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ARTICLE 
Zyderm collagen implant (ZCI), used in the treat- 
ment of scarring, soft tissue contour defects, and 
age lines, has been found to be both efficacious and 
safe. Over 40,000 individuals have received ZCI, 
with fewer than 2% showing adverse responses (data 
on file, Collagen Corporation, Palo Alto, Califor- 
nia). ZCI is comprised of highly purified bovine col- 
lagen that has undergone partial enzymatic degra- 
dation to reduce its antigenicity.’ Despite this 
purification, theoretical considerations have pre- 
cluded its use in patients with autoimmune dis- 
eases, such as lupus erythematosus, inflammatory 
bowel disease, Hashimoto’s thyroiditis, and pro- 
gressive systemic sclerosis. Morphea has not been 
considered on this list of contraindicated diseases. 
I t  is usually an isolated phenomenon with no pre- 
disposition to systemic disease. Our patient repre- 
sents the first case of ZCI used to treat cosmetically 
disfiguring localized morphea. ZCI injections were 
instituted following consultation and consent from 
the patient and representatives of the Collagen Cor- 
poration. 
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CASE REPORT 
The patient is a 25-year-old woman with a 4-year 
history of a sclerotic, atrophic, and somewhat hy- 
perpigmented 2.0 x 3.5 cm patch over her left lower 
eyelid, zygoma, and cheek (Fig. 1). Historically the 
lesion had not increased in size for 2 years and was 
thought to be clinically inactive. The patient had no 
signs or symptoms of concomitant connective tis- 
sue disease, and the physical examination was nor- 
mal. A biopsy of the lesion was consistent with 
morphea. Antinuclear antibody (ANA) and com- 
plete blood count were normal. ZCI test dose in- 
jected into her right volar forearm was nonreactive 
at 72 hours and at 1 month. At monthly intervals 
over the following 3 months, a total of 1.5 ml ZCI 
was implanted into the lesion up to, but not ex- 
tending over, the orbital rim. The patient achieved 
a very good clinical correction (80%) and was en- 
tirely satisfied with the cosmetic results (Fig. 2). This 
result has persisted for 1 year, and careful follow- 
up for loss of correction is anticipated. Prior to, dur- 
ing, and following ZCI therapy, anti-ZCI antibodies 
assays remained normal. The antibodies were 
measured in our laboratory using an ELISA assay 
developed and reported by Swanson et a1.* In this 
assay, the patient’s serum has remained well within 
normal limits for our laboratory. 
COMMENTS 
For this patient, ZCI was able to correct the contour 
defect caused by her disease. However, the implant 
had no effect on the hyperpigmentation on the 
sclerotic texture of the lesion. The latter is in con- 
trast to acne scarring, where ZCI often softens the 
existing scar (data on file, Collagen Corporation). 
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FIGURE 1. Pre-Zyderm implant. 
The presence of autoimmune connective tissue 
disease (CTD) is an absolute contraindication to the 
administration of ZCI. The diagnosis of one of these 
diseases is made through history, serologic testing, 
x-rays, and other diagnostic procedures. Patients 
with the variant en Coup de Sabre of linear sclero- 
derma have frequently been found to have positive 
ANA as well as other signs and symptoms of CTD.3,4 
Our patient, by history, physical examination, and 
laboratory findings, did not fit this subset of scler- 
oderma. Her disease was inactive, her physical ex- 
amination was entirely normal, and her ANA was 
negative. For these reasons, we thought she had 
localized morphea only, with no predisposition to 
systemic disease. Serologic testing for anti-ZCI an- 
tibodies was also negative. To date, this highly spe- 
cific test for anti-ZCI antibodies had been found 
positive in about 7% of the control population and 
100% of patients who have received ZCI and exhib- 
ited a positive skin test or treatment site reaction.5 
I t  is entirely possible that this assay can be used to 
screen patients a t  risk to develop adverse ZCI reac- 
tions. In doing so, the list of contraindicated dis- 
eases may be modified to allow more patients to 
receive ZCI. 
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FIGURE 2. A good correction (about 80%) following the 
injection of 1.5 ml of Zyderm. 
In summary, we present a new indication for ZCI. 
Although skin hyperpigmentation was not affected 
by the implants, the contour depression was ele- 
vated sufficiently to achieve satisfactory cosmesis. 
This correction has persisted to date, although we 
anticipate the need for reinjection to maintain cor- 
rection in the future. Finally, anti-ZCI antibodies 
were negative, suggesting that the risk of an ad- 
verse response was minimal. 
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